March 27, 2018 / 11:42 AM / a month ago

BRIEF-Arrowhead Pharmaceuticals Arrowhead Begins Dosing In Phase 1/2 Study Of ARO-HBV

March 27 (Reuters) - Arrowhead Pharmaceuticals Inc:

* ARROWHEAD BEGINS DOSING IN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF CHRONIC HEPATITIS B Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below